BeyondSpring Stock Price, News & Analysis (NASDAQ:BYSI)

$35.25 0.88 (2.56 %)
(As of 11/18/2017 09:24 AM ET)
Previous Close$35.25
Today's Range$35.25 - $35.20
52-Week Range$16.55 - $48.49
Volume860 shs
Average Volume2,169 shs
Market Capitalization$805.29 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About BeyondSpring (NASDAQ:BYSI)

BeyondSpring logoBeyondSpring Inc. is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). Plinabulin has also entered in a Phase I/II clinical trials to investigate its therapeutic potential in combination with the immuno-oncology agent nivolumab. The Company's BPI-002 program is based on an oral small molecule agent, which induces T-cell activation. The Company's IkappaB kinase (IKK) program, BPI-003, is based on a small molecule inhibitor of IKK, a protein kinase.


Industry, Sector and Symbol:
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Sector: Medical
  • Symbol: NASDAQ:BYSI
  • CUSIP: N/A
  • Web: www.beyondspringpharma.com
Debt:
  • Current Ratio: 14.02%
  • Quick Ratio: 14.02%
Sales & Book Value:
  • Annual Sales: N/A
  • Price / Sales: N/A
  • Book Value: $1.77 per share
  • Price / Book: 19.92
Misc:
  • Employees: 25
  • Outstanding Shares: 22,840,000
 

Frequently Asked Questions for BeyondSpring (NASDAQ:BYSI)

What is BeyondSpring's stock symbol?

BeyondSpring trades on the NASDAQ under the ticker symbol "BYSI."

How were BeyondSpring's earnings last quarter?

BeyondSpring Inc. (NASDAQ:BYSI) posted its quarterly earnings results on Thursday, November, 9th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.01. View BeyondSpring's Earnings History.

When will BeyondSpring make its next earnings announcement?

BeyondSpring is scheduled to release their next quarterly earnings announcement on Friday, April, 27th 2018. View Earnings Estimates for BeyondSpring.

Where is BeyondSpring's stock going? Where will BeyondSpring's stock price be in 2017?

3 Wall Street analysts have issued twelve-month price targets for BeyondSpring's stock. Their forecasts range from $50.00 to $60.00. On average, they expect BeyondSpring's share price to reach $54.00 in the next twelve months. View Analyst Ratings for BeyondSpring.

What are Wall Street analysts saying about BeyondSpring stock?

Here are some recent quotes from research analysts about BeyondSpring stock:

  • 1. According to Zacks Investment Research, "BeyondSpring Inc. is a clinical stage biopharmaceutical company. It focused on the development of cancer therapies. The Company's lead product consists of into a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical trial in the prevention of chemotherapy-induced Neutropenia. BeyondSpring Inc. is based in New York, United States. " (11/13/2017)
  • 2. Maxim Group analysts commented, "BeyondSpring announced that the enrollment of the first patient in China for Plinabulin (P2/3 trial) in the Harbin Medical University Cancer Hospital in Harbin, China. This news follows other recent positives which include: ○ Positive Regulatory Reforms in China. The State Council of China announced on October 8, 2017 regulatory reforms, which could translate into an accelerated review (shorter time to the marketplace). Our current timeline assumes approvals and launch in China by 2020. This news is consistent with what we are hearing amongst our other covered companies in China such as BeiGene (BGNE – $80.01 – Buy). ○ Two China-based Grants. The first from the city government of Dalian, China. The second from the Dalian Economic Development Park. Conclusion: Plinabulin could become the standard of care for chemo patients as a prophylactic treatment for the CIN indication alone. The market opportunity extends beyond the $8B biologics market and could be upwards of $30B." (10/27/2017)

Who are some of BeyondSpring's key competitors?

When did BeyondSpring IPO?

(BYSI) raised $4 million in an initial public offering (IPO) on Thursday, March 9th 2017. The company issued 200,000 shares at $20.00 per share. Rodman & Renshaw (a Unit of H.C. Wainwright & Co.) served as the underwriter for the IPO.

How do I buy BeyondSpring stock?

Shares of BeyondSpring can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BeyondSpring's stock price today?

One share of BeyondSpring stock can currently be purchased for approximately $35.25.

How big of a company is BeyondSpring?

BeyondSpring has a market capitalization of $805.29 million. BeyondSpring employs 25 workers across the globe.

How can I contact BeyondSpring?

BeyondSpring's mailing address is 28 LIBERTY STREET 39TH FLOOR, NEW YORK NY, 10005. The company can be reached via phone at 646-528-4184 or via email at [email protected]


MarketBeat Community Rating for BeyondSpring (NASDAQ BYSI)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  50 (Vote Outperform)
Underperform Votes:  46 (Vote Underperform)
Total Votes:  96
MarketBeat's community ratings are surveys of what our community members think about BeyondSpring and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for BeyondSpring (NASDAQ:BYSI)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 3 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $54.00 (53.19% upside)

Consensus Price Target History for BeyondSpring (NASDAQ:BYSI)

Price Target History for BeyondSpring (NASDAQ:BYSI)

Analysts' Ratings History for BeyondSpring (NASDAQ:BYSI)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/27/2017Maxim GroupReiterated RatingBuy$52.00N/AView Rating Details
10/26/2017HC WainwrightSet Price TargetBuy$60.00N/AView Rating Details
7/14/2017Rodman & RenshawBoost Price TargetBuy -> Buy$43.00 -> $50.00MediumView Rating Details
(Data available from 11/19/2015 forward)

Earnings

Earnings History and Estimates Chart for BeyondSpring (NASDAQ:BYSI)

Earnings by Quarter for BeyondSpring (NASDAQ:BYSI)

Earnings History by Quarter for BeyondSpring (NASDAQ BYSI)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/27/2018        
11/9/2017Q3 2017($0.69)($0.68)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for BeyondSpring (NASDAQ:BYSI)
Current Year EPS Consensus Estimate: $-4.41 EPS
Next Year EPS Consensus Estimate: $-4.53 EPS

Dividends

Dividend History for BeyondSpring (NASDAQ:BYSI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for BeyondSpring (NASDAQ BYSI)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for BeyondSpring (NASDAQ BYSI)

Source:
DateHeadline
 BeyondSpring Inc. (BYSI) Given $56.00 Average Target Price by Brokerages BeyondSpring Inc. (BYSI) Given $56.00 Average Target Price by Brokerages
www.americanbankingnews.com - November 15 at 5:06 AM
BeyondSpring Inc. (BYSI) Lowered to "Sell" at Zacks Investment ResearchBeyondSpring Inc. (BYSI) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - November 13 at 8:30 PM
BeyondSpring Inc. (BYSI) Posts Quarterly  Earnings Results, Beats Expectations By $0.01 EPSBeyondSpring Inc. (BYSI) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - November 10 at 12:51 PM
BeyondSpring Reports Third Quarter 2017 Operational and Financial ResultsBeyondSpring Reports Third Quarter 2017 Operational and Financial Results
finance.yahoo.com - November 9 at 6:16 PM
Zacks: BeyondSpring Inc. (BYSI) Receives Consensus Rating of "Strong Buy" from AnalystsZacks: BeyondSpring Inc. (BYSI) Receives Consensus Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - November 9 at 11:46 AM
BeyondSpring Inc. (BYSI) Set to Announce Quarterly Earnings on ThursdayBeyondSpring Inc. (BYSI) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - November 3 at 10:59 AM
BeyondSpring to Host Quarterly Operational Update Conference Call on November 9, 2017BeyondSpring to Host Quarterly Operational Update Conference Call on November 9, 2017
finance.yahoo.com - November 2 at 5:34 PM
BeyondSpring Announces the First Patient Enrolled in China in its Global Phase 2/3 Trial with Plinabulin for the Prevention of Chemotherapy-Induced NeutropeniaBeyondSpring Announces the First Patient Enrolled in China in its Global Phase 2/3 Trial with Plinabulin for the Prevention of Chemotherapy-Induced Neutropenia
finance.yahoo.com - October 26 at 8:48 AM
HC Wainwright Boosts BeyondSpring Inc. (BYSI) Price Target to $60.00HC Wainwright Boosts BeyondSpring Inc. (BYSI) Price Target to $60.00
www.americanbankingnews.com - October 26 at 7:38 AM
Zacks: BeyondSpring Inc. (BYSI) Receives Consensus Rating of "Strong Buy" from BrokeragesZacks: BeyondSpring Inc. (BYSI) Receives Consensus Rating of "Strong Buy" from Brokerages
www.americanbankingnews.com - October 24 at 9:18 AM
BeyondSpring Receives Two Grants in China to Further Develop Innovative Drug PipelineBeyondSpring Receives Two Grants in China to Further Develop Innovative Drug Pipeline
finance.yahoo.com - October 23 at 5:44 PM
BeyondSpring Becomes Oversold (BYSI)BeyondSpring Becomes Oversold (BYSI)
www.thestreet.com - October 20 at 11:39 PM
BeyondSpring Chief Medical Officer to Present at the 2017 BIO Investor Forum on Oct. 18 in San FranciscoBeyondSpring Chief Medical Officer to Present at the 2017 BIO Investor Forum on Oct. 18 in San Francisco
feeds.benzinga.com - October 18 at 8:55 AM
-$0.69 Earnings Per Share Expected for BeyondSpring Inc. (BYSI) This Quarter-$0.69 Earnings Per Share Expected for BeyondSpring Inc. (BYSI) This Quarter
www.americanbankingnews.com - September 26 at 10:10 AM
BeyondSpring Looks to Future After IPO/PIPE LaunchBeyondSpring Looks to Future After IPO/PIPE Launch
finance.yahoo.com - September 15 at 10:17 PM
BeyondSpring (BYSI) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - SlideshowBeyondSpring (BYSI) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 13 at 11:02 PM
Analysts Expect BeyondSpring Inc. (BYSI) to Announce ($0.69) EPSAnalysts Expect BeyondSpring Inc. (BYSI) to Announce ($0.69) EPS
www.americanbankingnews.com - September 13 at 2:53 PM
Good News For Nightstar And BiotechGood News For Nightstar And Biotech
seekingalpha.com - September 5 at 6:28 PM
BeyondSpring to Present at the 19th Annual Rodman & Renshaw Global Investment ConferenceBeyondSpring to Present at the 19th Annual Rodman & Renshaw Global Investment Conference
finance.yahoo.com - September 5 at 6:28 PM
BeyondSpring Inc.s (BYSI) Lock-Up Period Set To Expire  on September 5thBeyondSpring Inc.'s (BYSI) Lock-Up Period Set To Expire on September 5th
www.americanbankingnews.com - September 2 at 1:22 AM
Brokerages Anticipate BeyondSpring Inc. (BYSI) to Announce ($0.69) EPSBrokerages Anticipate BeyondSpring Inc. (BYSI) to Announce ($0.69) EPS
www.americanbankingnews.com - August 24 at 12:44 PM
BeyondSpring Provides Operational Update for Second Quarter of 2017BeyondSpring Provides Operational Update for Second Quarter of 2017
finance.yahoo.com - August 21 at 4:46 PM
BeyondSprings (BYSI) "Buy" Rating Reiterated at HC WainwrightBeyondSpring's (BYSI) "Buy" Rating Reiterated at HC Wainwright
www.americanbankingnews.com - August 21 at 1:38 PM
BeyondSpring Inc. (BYSI) Releases Quarterly  Earnings Results, Misses Expectations By $0.10 EPSBeyondSpring Inc. (BYSI) Releases Quarterly Earnings Results, Misses Expectations By $0.10 EPS
www.americanbankingnews.com - August 21 at 9:02 AM
 BeyondSpring Inc. (BYSI) Given Consensus Recommendation of "" by Analysts BeyondSpring Inc. (BYSI) Given Consensus Recommendation of "" by Analysts
www.americanbankingnews.com - August 18 at 6:32 PM
BeyondSpring to Present at the 2017 Southern California Investor ConferenceBeyondSpring to Present at the 2017 Southern California Investor Conference
finance.yahoo.com - August 17 at 6:11 PM
BeyondSpring to Host Quarterly Operational Update Conference Call on August 21, 2017BeyondSpring to Host Quarterly Operational Update Conference Call on August 21, 2017
finance.yahoo.com - August 14 at 5:18 PM
BeyondSpring Inc. (BYSI) Set to Announce Quarterly Earnings on MondayBeyondSpring Inc. (BYSI) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - August 14 at 2:56 AM
 Analysts Anticipate BeyondSpring Inc. (BYSI) to Announce -$0.24 Earnings Per Share Analysts Anticipate BeyondSpring Inc. (BYSI) to Announce -$0.24 Earnings Per Share
www.americanbankingnews.com - August 2 at 12:16 AM
BeyondSpring Inc. (NASDAQ:BYSI) Price Target Increased to $50.00 by Analysts at Rodman & RenshawBeyondSpring Inc. (NASDAQ:BYSI) Price Target Increased to $50.00 by Analysts at Rodman & Renshaw
www.americanbankingnews.com - July 14 at 9:06 AM
China FDA Approves CTAs for BeyondSpring’s Second Global Plinabulin Registrational Trial for Chemotherapy-Induced Neutropenia PreventionChina FDA Approves CTAs for BeyondSpring’s Second Global Plinabulin Registrational Trial for Chemotherapy-Induced Neutropenia Prevention
finance.yahoo.com - July 6 at 6:10 PM
BeyondSpring Chief Medical Officer to Present Clinical Data for Lead Asset Plinabulin at 2017 BIO International Convention in San DiegoBeyondSpring Chief Medical Officer to Present Clinical Data for Lead Asset Plinabulin at 2017 BIO International Convention in San Diego
feeds.benzinga.com - June 15 at 9:59 AM

Social Media

Financials

Chart

BeyondSpring (NASDAQ BYSI) Chart for Sunday, November, 19, 2017
Loading chart…

This page was last updated on 11/19/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.